CVS Health has shown a strong turnaround with accelerating earnings, improved margins, and reduced debt, leading to an upgrade from hold to buy with a $115 price target. The company’s solid free cash flow and low dividend payout ratio enhance dividend safety, appealing to income-focused investors despite potential near-term volatility from upcoming earnings and 2027 challenges. This improved outlook reflects CVS's effective execution and valuation that offers upside for risk-tolerant investors.
CVS Health offers a near 3% dividend yield at 2.92%, attracting income-focused investors as highlighted in the news. On Pluang, CVS shares trade at USD 90.67 with a slight 0.50% decline as of Oct 28, 2026 23:31 WIB, while the platform shows strong buying interest with 92% of orders to buy. This aligns with the article's view of meaningful upside potential despite some near-term volatility.
